Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The ACUITY Trial: A Randomized Comparison of Angiomax (Bivalirudin) Versus Heparin (Unfractionated Heparin or Enoxaparin) in Patients Undergoing Early Invasive Management for Acute Coronary Syndromes Without ST-Segment Elevation

NCT00093158 is registered in ClinicalTrials.gov with The Medicines Company as lead sponsor.

NCT NCT00093158
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00093158 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The ACUITY Trial: A Randomized Comparison of Angiomax (Bivalirudin) Versus Heparin (Unfractionated Heparin or Enoxaparin) in Patients Undergoing Early Invasive Management for Acute Coronary Syndromes Without ST-Segment Elevation
Lead sponsor
The Medicines Company
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2003
Completion date
January 31, 2007
Enrollment
13,800
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute disease, myocardial infarction, unstable angina